Clini Cancer Res: Navu suprets treatment for advanced platinum-resistant urethria skin cancer.
-
Last Update: 2020-07-30
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
!---- Purpose: To report its effectiveness and safety by prolonging follow-up and exploratory biomarker analysis of The Ii CheckMate 275 trial to identify predictable platinum-resistant metastasis or non-removable urinary skin cancer (mUC) reactive biomarkers for Navuzumab resistance treatment.method: Patients receive navuzumabaditis for 3 mg/kg?2 weeks until the condition progresses, intolerable toxicity or other predetermined factors. The main endpoint ofis objective mitigation rate (ORR).secondary endpoint is a progression-free survival period.exploratory endpoints are biomarker analysis of safety and tumor mutation load (TMB), PD-L1, and previously clear mutation characteristics.results: Of the 270 patients treated, 139 had assessable TMB.had a minimum follow-up of 33.7 months, with ORR, median PFS and median OS at 20.7%, 1.9 months and 8.6 months, respectively. there are no new security issues.high TMB is associated with ORR, PFS, and OS improvement (p.lt;0.05).TMB joint PD-L1 can better predict ORR, PFS and OS than single-use PD-L1.high mutation feature 2 score was more associated with OS, but not with the increase in the predictive value of TMB.Conclusion: These results support the continuous anti-tumor activity of navusm, suggesting better remission of TMB or enriched mUC.in randomized trials, future studies of TMB/PD-L1 as a biomarker of navusm reaction were worth it..
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
